But if you're looking at what could be more immediate term potential catalysts, take these in:
No. 1 CTXR Potential Catalyst - Analyst Coverage With Major P.T.
Maxim Group - $4.00 Price Target
Here is part of the summary from the November 30th Maxim Group analyst report:
- Citius Pharmaceuticals is a late-stage company with two 'de-risked' P3 assets: Mino-Lok in catheter-related bloodstream infection (CRBSI) and I/ONTAK in cutaneous T-cell lymphoma (CTCL).
- Mino-Lok is currently in P3 with a readout expected in C1H22 and an NDA to follow. The dr-ug itself has demonstrated 100% clearance of infection-causing biofilms in P2b and has the potential to salvage catheters, avoiding a $10K remove and replace procedure.
- Conclusion. With ~$70M in cash, Citius is funded through pivotal readouts in C1H22, which represent potentially transformative catalysts, in our view. Both assets address areas of high unmet need, and have commercial synergies due to a shared target customer (oncology). With prior data supporting I/ONTAK and Mino-Lok, we consider the risk/reward profile favorable.
From Friday's close, this $4.00 price target provides upside potential over 100%.
Now, I'm not saying CTXR is going to go soaring to $4.00 today, but you need to be aware of this analyst provided potential upside.
No. 2 CTXR Potential Catalyst - Oversold Leaning Technicals, Bounce Potential
As of close on Friday, Barchart was reporting this profile to have several oversold leaning technicals.
These technicals could be signaling a healthy reversal in the near term for CTXR.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of close Friday) that could signal CTXR to be leaning oversold and on the verge of a potential reversal.
- 9-Day Relative Strength Index: 23.72%
- 14-Day Relative Strength Index: 27.32%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 2.94%
- 14-Day Williams %R: 97.06%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
No. 3 CTXR Potential Catalyst - Reporting Of Major Institutional Buying
Over at WhaleWisdom, some interesting developments have been reported over the last 30 days.
Here's a quick breakdown:
(1.) Wells Fargo & Company added a big time position to their portfolio.
Reported on 11/15/21, the company purchased approximately 6.44K+ shares at a market value of approximately $1.31Mn.
(2.) American in-vestment ad-visor, Vanguard Group, added to their position with a purchase of approximately 125K shares (approx. 5.77Mn overall) as reported on 11/12/21.
(3.) Also adding to their position was in-vestment management company, BlackRock Inc., who further increased their totals to an amount of approx. 8.15Mn shares (reported on 11/9/21).
Don't think twice about this. This is huge news and only the tip of the iceberg.
Just take a look at WhaleWisdom's site and you'll see how many different institutions are taking positions in CTXR.
Could it be that these institutions see a big future for this Nasdaq profile?
No. 4 CTXR Potential Catalyst - Experienced Hire Could Add Serious Value To Company
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls
CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs.
Read the full article here.
No. 5 CTXR Potential Catalyst - Company Being Added To Russell 2000® Index
Citius Pharmaceuticals to be Added to Russell 2000® Index
CRANFORD, N.J., June 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.
"Our inclusion in the Russell index is an important milestone for Citius that reflects the continued progress we are making to develop and commercialize first-in-class treatment options for patients around the world. We welcome the enhanced visibility of our diversified pipeline and long-term growth potential, and look forward to sharing our future milestones with a broader investment community," said Myron Holubiak, President and Chief Executive Officer of Citius.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership in the small-cap Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. Citius st-ock will also be automatically added to the appropriate growth and value indexes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9Tn in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Read the full article here.